Skip to main content

Table 1 General information

From: Clinical analysis of chronic active EBV infection with coronary artery dilatation and a matched case–control study

Pt

Sex

Onset age (years) (岁)

Final diagnosis

Treatment

Time of CAD recovery

Duration of follow-up (month)

Result

1

F

10.5

CAEBV

L-DEP

Non-recovered

8.0

Alive

2

M

6.3

CAEBV

Abandon

Non-recovered

12.0

Alive

3

M

12.2

CAEBV, HLH

Abandon

Non-recovered

13.0

Alive

4

F

5.8

CAEBV

Abandon

Non-recovered

27.0

Alive

5

M

14.3

CAEBV

L-DEP

18 days

28.0

Alive

6

M

3.2

CAEBV

L-DEP, HSCT

68 days

28.0

Alive

7

M

7.6

CAEBV

L-DEP, HSCT

Non-recovered

6.0

Dead

8

F

4.3

CAEBV

L-DEP, HSCT

Non-recovered

48.0

Alive

9

F

2.8

CAEBV,HLH

L-DEP

Non-recovered

8.0

Alive

10

M

5.0

CAEBV, HLH

L-DEP, HSCT

21 days

30.0

Alive

  1. Pt patient, CAEBV chronic active Epstein–Barr virus infection, HLH hemophagocytic lymphohistiocytosis, CAD coronary artery dilatation, L-DEP PEG-Aspegaspargase, doxorubicin, etoposide and methylprednisolone, time of CAD recovery the time from discovery of CAD to recovery